Skip to main content
OpenTrials
Recruiting

NCT Number: NCT02747888

Hereditary Risk Factors for Thyroid Cancer

Thyroid cancers can occur sporadically, but can also be found as tumors that cluster in families with other cancers or genetic syndromes. Researchers are studying thyroid cancer in children and families, with a particular interest in understanding genes and other factors that may put individuals at risk for developing thyroid cancer and thyroid nodules.

* In this study, family and medical history information is collected alongside a blood or saliva sample for genetic studies. * Individuals with a past or present childhood thyroid cancer/nodule or a thyroid cancer suspected to be inherited in their family are invited to participate.

Recruiting

Interested in participating?

Request Info

Key information

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Dana Farber Cancer Institute

Boston, Massachusetts, 02115, United States

Location status: Recruiting

Location contact

Junne Kamihara, MD, PhD

CONTACT

617.632.3044

Junne Kamihara, MD, PhD

PRINCIPAL_INVESTIGATOR

About this study

The purpose of this research study is to learn more about risk factors for inherited thyroid cancer.

The investigators would like to use the participant DNA to look for alterations in genes. The investigator will perform DNA sequencing and other genetic studies to identify errors in the genes that may contribute to the formation of thyroid nodules and cancer.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Individual pediatric patient with current or previous known or suspected thyroid cancer or nodule(s).
  • Individual adult patient with current or previous known or suspected thyroid cancer or nodule(s) if they come from a family with a high suspicion of hereditary cancer (as below).
  • Individuals from families with a high suspicion of hereditary thyroid cancer:
  • Families with a current or previous diagnosis of a thyroid cancer/nodule occurring in childhood (<18 years old).
  • Families with a high suspicion of hereditary thyroid cancer/nodules other than above to include:
  • Families with thyroid cancer in multiple individuals
  • Families with thyroid cancer and a known genetic syndrome
  • Families with thyroid cancer and a suspected genetic syndrome (e.g. multiple childhood cancers in the family, multiple primary cancers, multiple endocrinopathies, etc.)

Exclusion criteria

  • Individuals who are unable to give informed consent.
  • Individuals who are unable to complete study materials.

Treatment and study plan

•Referral to Genetic Counselor, if indicated

Genetic

Primary outcomes

  1. Number of participants who have childhood or suspected familial thyroid nodules/cancer

    Time frame: 2 years

  2. Number of germline mutations identified associated with thyroid cancer predisposition

    Time frame: 2 years

  3. Prevalence of suspected familial thyroid cancer among those with childhood thyroid nodules/cancer

    Time frame: 2 years

Study contacts

Contact information is provided by the study sponsor or research team.

Junne Kamihara, MD, PhD

CONTACT

[email protected]

617.632.3044

Sarah Hunt, MPH

CONTACT

[email protected]

Sponsors and collaborators

Lead sponsor

Dana-Farber Cancer Institute

Other

Registry information

Important dates

Study start
2016
Primary completion
2029
Study completion
2029
First posted
Apr 22, 2016
Registry last updated
Jun 11, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.